These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 14671495)
1. Celebrating the SSCI: the drug discovery pathway: challenges and pitfalls. Bennett JC Am J Med Sci; 2003 Dec; 326(6):329-32. PubMed ID: 14671495 [No Abstract] [Full Text] [Related]
2. Strategies for success in drug development. Wardell WM Retina; 2005 Dec; 25(8 Suppl):S100-S102. PubMed ID: 16374309 [No Abstract] [Full Text] [Related]
3. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Lee LS; Nafziger AN; Bertino JS Clin Pharmacol Ther; 2005 Jul; 78(1):1-6. PubMed ID: 16003286 [No Abstract] [Full Text] [Related]
5. Less is more: the human microdosing concept. Garner RC Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185 [No Abstract] [Full Text] [Related]
6. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK. Cavero I Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268 [TBL] [Abstract][Full Text] [Related]
7. Improved early clinical development through human microdosing studies. Wilding IR; Bell JA Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808 [No Abstract] [Full Text] [Related]
8. Backup programs in drug discovery. Greenlee WJ; Desai M Curr Opin Drug Discov Devel; 2006 Jul; 9(4):412-3. PubMed ID: 16889224 [No Abstract] [Full Text] [Related]
9. Discovery of a new drug--from target identification to ultra-high-throughput screening. Golz S; Hüser J Clin Lab; 2007; 53(1-2):77-9. PubMed ID: 17323829 [No Abstract] [Full Text] [Related]
10. Application of high-throughput screening techniques to drug discovery. Cox B; Denyer JC; Binnie A; Donnelly MC; Evans B; Green DV; Lewis JA; Mander TH; Merritt AT; Valler MJ; Watson SP Prog Med Chem; 2000; 37():83-133. PubMed ID: 10845248 [No Abstract] [Full Text] [Related]
11. The test of public scrutiny. Mallinckrodt CH Pharm Stat; 2006; 5(4):249-52. PubMed ID: 17219626 [No Abstract] [Full Text] [Related]
12. Preclinical drug discovery research and training at Vanderbilt. Lindsley CW; Weaver D; Jones C; Marnett L; Conn PJ ACS Chem Biol; 2007 Jan; 2(1):17-20. PubMed ID: 17243778 [No Abstract] [Full Text] [Related]
13. Drug discovery: Chemical beauty contest. Leeson P Nature; 2012 Jan; 481(7382):455-6. PubMed ID: 22281594 [No Abstract] [Full Text] [Related]
14. DNA vaccines forum: how to enhance DNA vaccines safety and potency? Ulmer JB IDrugs; 2005 May; 8(5):357-9. PubMed ID: 15883908 [No Abstract] [Full Text] [Related]
15. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
16. Use of high-content analysis for compound screening and target selection. Rausch O IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic studies in drug product development. Meibohm B; Derendorf H J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894 [TBL] [Abstract][Full Text] [Related]
18. Hit discovery and hit-to-lead approaches. Keseru GM; Makara GM Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802 [TBL] [Abstract][Full Text] [Related]
19. In vitro studies in drug discovery and development: an analysis of study objectives and application of good laboratory practices (GLP). Bajpai M; Esmay JD Drug Metab Rev; 2002 Nov; 34(4):679-89. PubMed ID: 12487146 [TBL] [Abstract][Full Text] [Related]
20. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development. Korstanje C Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643 [No Abstract] [Full Text] [Related] [Next] [New Search]